The pharmaceutical landscape is rapidly changing as patents for some of the blockbuster drugs of the last decade near expiration and other players try to grab some of the remaining revenues before ge

It's not easy to admit you're wrong. I don't typically keep up with "new technology." In fact, I've often been accused of living in the past. So, when I found out about Twitter --

Editor's Note: The following article was written by Raymond James Chief Investment Strategist Jeff Saut. It has been produced with permission for the benefit of the Minyanville community.Minyan

1. The Economic Crisis Takes a Virulent TurnThe word credit comes from the Latin "credere" which means "to believe, or to trust." That's really all you need to know about the mode

Editor's Note: This is Part 2 in a multiple-part series. Part 1 can be found here, Part 3 can be found here, and Part 4 can be found here.As an improvement on writing covered calls, Steve Smith's art

Money is a difficult subject. There's much confusion as to what it is. There's even more confusion as to the best way to measure it. Yet, before we can measure it, we have to define it.Here's a descr

A reader writes:  I’m hoping for a more in-depth “beta” on gamma. I'm hoping you will address trading gamma in an article; how you use gamma to spot trading opportunities, w

Last Thursday, I received an email concerning debt deflation from David Meier, associate adviser at the MotleyFool.David asked if I had any comments on his article Debt-deflation: Just the beginning?

What does it say that I was (again) vilified on the MarketWatch message boards for proactively offering that the hedge fund industry compensatory structure will meaningfully shift and those rooting f

Editor's Note: This article was written by Minyan Kevin Dougherty, a portfolio manager at Pharos Financial Group, a specialist investor in emerging markets. Kevin manages three funds, the Pharos